As part of its ongoing efforts to fight COVID-19, the U.S. Food and Drug Administration today broadened the scope of the existing emergency use authorization (EUA) for the drug Veklury (remdesivir) to...

The U.S. Food and Drug Administration (FDA) issued an emergency use authorization (EUA) today for investigational convalescent plasma for the treatment of COVID-19 in hospitalized patients as part of the...

The American College of Medical Toxicology (ACMT), the American Academy of Clinical Toxicology (AACT), and the American Association of Poison Control Centers has issued the following joint statement in...

Gilead Sciences, Inc. announced Monday that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for Veklury® (remdesivir), an investigational antiviral for the...

Bayer announced today that the United States Food and Drug Administration (FDA) has approved Lampit® (nifurtimox) for use in pediatric patients (from birth to less than 18 years of age and weighing at...

What started off as basic research 25 years ago has now lead to a successfully approved drug: The entry blocker bulevirtide (brand name Hepcludex, formerly known as Myrcludex B), jointly developed by researchers...

A recent meningitis case at Children’s National Hospital raises serious concerns about antibiotic resistance in the common bacterium that caused it, researchers from the hospital write in a case...

More than 600,000 people worldwide have fallen victim to the lung disease COVID-19 so far, which is caused by the SARS coronavirus-2 (SARS-CoV-2). In order to obtain an effective therapy for COVID-19 as...

Yellow fever, a hemorrhagic disease that is common in South America and sub-Saharan Africa, infects about 200,000 people per year and causes an estimated 30,000 deaths. While there is a vaccine for yellow...

NeuroRx, Inc., in partnership with RELIEF THERAPEUTICS Holdings AG today announced that the independent Data Monitoring Committee has reviewed the findings in the first 30 patients treated in Fast Track...